P2RY12 and prostate carcinoma: It was assumed that when platelets are exposed to prostate cancer cells, integrin αIIbβ3-FcγRIIa-P2Y12 cross-talk transduces the signal to release ADP whose receptor P2Y12 amplifies the response, thereby promoting platelet aggregation.